Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | THRB | P10828 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tetrahydrofuran SCHEMBL9877354 | 1.00 | LMNA (0.60) | LMNAALDH1A1THRBCYP3A4CYP2C19 | |
| SCHEMBL6867778 | 0.98 | LMNA (0.57) | LMNAALDH1A1THRB | |
| SCHEMBL2702135 | 0.98 | LMNA (0.57) | LMNAALDH1A1THRB | |
| Dioxane SCHEMBL7672675 | 0.90 | LMNA (0.67) | LMNAALDH1A1THRBCYP3A4CYP2C19 | |
| SCHEMBL767256 | 0.86 | LMNA (0.55) | LMNATHRB | |
| Tetrahydrofuran SCHEMBL9464976 | 0.85 | ALDH1A1 (0.40) | LMNAALDH1A1THRBCYP3A4CYP2C19 | |
| Tetrahydrofuran SCHEMBL9148484 | 0.84 | LMNA (0.43) | LMNA | |
| Tetrahydrofuran SCHEMBL10505828 | 0.82 | THRB (0.58) | LMNAALDH1A1THRB | |
| Tetrahydrofuran SCHEMBL28175157 | 0.81 | ALDH1A1 (0.36) | LMNAALDH1A1THRBCYP3A4CYP2C19 | |
| Cyclopropane SCHEMBL1406305 | 0.81 | LMNA (0.80) | LMNATHRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1121351-A4 | PREPARATION OF (S)-2-AMINO-6,6-DIMETHOXYHEXANOIC ACID METHYL ESTER VIA NOVEL DIOXOLANES | BRISTOL MYERS SQUIBB CO (US) | 2003-05-02 | — | — | EP | claimed |
| US-6329542-B1 | GLYCINAMIDE DERIVATIVE IS REACTED WITH DIOXOLANE COMPOUND, TREATING INTERMEDIATE WITH WATER AND REFLUXING TO GIVE DIOXOLANE PENTANOIC ACID COMPOUND WHICH IS TREATED TO EXCHANGE THE DIOXOLANE ACETAL WITH A DIMETHOXY ACETAL, ESTERIFICATION | BRISTOL-MYERS SQUIBB CO. | 2001-12-11 | — | — | US | claimed |
| EP-1121351-A2 | PREPARATION OF (S)-2-AMINO-6,6-DIMETHOXYHEXANOIC ACID METHYL ESTER VIA NOVEL DIOXOLANES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2001-08-08 | — | — | EP | claimed |
| US-6248882-B1 | VIA DIOXOLANE INTERMEDIATES | BRISTOL-MYERS SQUIBB CO. | 2001-06-19 | — | — | US | claimed |
| WO-2000003981-A2 | PREPARATION OF (S)-2-AMINO-6,6-DIMETHOXYHEXANOIC ACID METHYL ESTER VIA NOVEL DIOXOLANES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2000-01-27 | — | — | WO | claimed |
| CN-113402493-A | Cyclocarboxylation soybean oil (methyl) acrylate resin and preparation method thereof | 新丰见微化工实业有限公司 | 2021-09-17 | — | — | CN | disclosed |
| CN-106456781-B | Hydroalcoholic system for nail treatment | 圣地亚哥-德孔波斯特拉大学 | 2020-07-10 | — | — | CN | disclosed |
| US-9669095-B2 | Cyclosporin analogues for preventing or treating hepatitis C infection | ENANTA PHARMACEUTICALS, INC. (US) | 2017-06-06 | — | — | US | disclosed |
| CN-106456781-A | Hydroalcoholic system for nail treatment | 圣地亚哥-德孔波斯特拉大学 | 2017-02-22 | — | — | CN | disclosed |
| EP-2367816-B1 | ISATIN DERIVATIVES FOR USE AS IN VIVO IMAGING AGENTS | IMP INNOVATIONS LTD (GB) | 2016-11-09 | — | — | EP | disclosed |
| US-20160130304-A1 | NOVEL CYCLOSPORIN ANALOGUES FOR PREVENTING OR TREATING HEPATITIS C INFECTION | ENANTA PHARMACEUTICALS, INC. | 2016-05-12 | — | — | US | disclosed |
| WO-2016073480-A1 | NOVEL CYCLOSPORIN ANALOGUES FOR PREVENTING OR TREATING HEPATITIS C INFECTION | ENANTA PHARMACEUTICALS, INC. (US) | 2016-05-12 | — | — | WO | disclosed |
| EP-0790971-B1 | PROCESS FOR THE REMOVAL OF COLOR FORMING MATERIAL FROM 1,4 BUTANEDIOL AND ITS APPLICATION TO THE PREPARATION OF PTMEG | DU PONT (US) | 2001-02-07 | — | — | EP | disclosed |
| US-6166227-A | Preparation of (S)-2-amino-6, 6-dimethoxyhexanoic acid methyl ester via novel dioxolanes | BRISTOL-MYERS SQUIBB CO. (US) | 2000-12-26 | — | — | US | disclosed |
| US-6140088-A | Stereoselective reductive amination of ketones | BRISTOL-MYERS SQUIBB COMPANY (US) | 2000-10-31 | — | — | US | disclosed |
| WO-2000004179-A1 | STEREOSELECTIVE REDUCTIVE AMINATION OF KETONES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2000-01-27 | — | — | WO | disclosed |
| WO-2000003981-A2 | PREPARATION OF (S)-2-AMINO-6,6-DIMETHOXYHEXANOIC ACID METHYL ESTER VIA NOVEL DIOXOLANES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2000-01-27 | — | — | WO | disclosed |
| EP-0790971-A1 | PROCESS FOR THE REMOVAL OF COLOR FORMING MATERIAL FROM 1,4 BUTANEDIOL AND ITS APPLICATION TO THE PREPARATION OF PTMEG | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1997-08-27 | — | — | EP | disclosed |
| US-5596074-A | Method for controlling color formation during polytetramethylene ether glycol production | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1997-01-21 | — | — | US | disclosed |
| WO-1996014281-A1 | PROCESS FOR THE REMOVAL OF COLOR FORMING MATERIAL FROM 1,4 BUTANEDIOL AND ITS APPLICATION TO THE PREPARATION OF PTMEG | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1996-05-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160130304-A1 | NOVEL CYCLOSPORIN ANALOGUES FOR PREVENTING OR TREATING HEPATITIS C INFECTION | HAVCR2, CHP1, MAVS | LMNA 4263/4885ALDH1A1 3792/4885THRB 4777/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.